ClinicalTrials.gg
CompletedNCT01678573Updated Sep 6, 2013

A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants

A Phase 1 interventional study of Treatment A: abiraterone acetate and Treatment B: abiraterone acetate in Healthy, sponsored by Janssen Research & Development, LLC. Completed at 1 site in China. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-09-06.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The purpose of this study is to evaluate the pharmacokinetics (how the drug concentrations change over time) of abiraterone acetate after oral administration of abiraterone acetate at different dose levels of 250, 500, and 1000 mg in healthy Chinese male participants under fasted conditions.

Read the detailed description

This is an open-label (all people know the identity of the intervention), randomized (the treatment sequence is assigned by chance), 3-way crossover study (method used to switch participants from one dose level to another in a clinical study) of single doses of abiraterone acetate in healthy Chinese male participants. The study consists of 3 phases: screening, open-label treatment, and follow up phases. After screening, randomly assigned participants will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to a randomized schedule under fasted conditions (Sequence 1 = ABC; Sequence 2 = BAC; and Sequence 3 = CBA). Each treatment period will be separated by a washout period (period when participant is not receiving any study medication) of at least 7 days. In the follow-up phase, study-related adverse events will be monitored by the investigator. Serial blood samples for pharmacokinetic analysis will be collected and safety will be monitored throughout the study. The total study duration will be approximately 42 days.

02

Conditions studied

  • Healthy

Keywords

  • Healthy
  • Pharmacokinetics
  • Abiraterone acetate
  • Abiraterone
  • JNJ-212082
  • Zytiga
  • Chinese
  • Fasted
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • within 18 to 27 kg/m2 (inclusive) and body weight above 50 kg at screening
  • Protocol-defined laboratory and parameters
  • Negative test results for selected medications and substances of abuse and negative exhaled carbon monoxide test at check-in day of each period
  • Agrees to protocol-defined use of effective
  • Willing to be confined at the clinical research facility for time period specified in the protocol

Exclusion criteria

Exclusion Criteria:

  • Significant history or current manifestation of any significant metabolic, allergic, dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder
  • History of reaction to the study medication or related compounds or used in the formulation
  • Confirmed hepatitis A, B, or C infection or (HIV) 1 or HIV-2 infection at screening
  • Serum testosterone level of \<200 ng/dL
  • Use of any tobacco or nicotine-containing products
  • Known or suspected use of illicit drugs in the last year
  • Protocol medications/preparations (prescription and non-prescription)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Sequence 1: abiraterone acetate

    Randomly assigned participants in Sequence 1 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule "ABC" under fasted conditions.

    Drug: Treatment A: abiraterone acetate · Drug: Treatment B: abiraterone acetate · Drug: Treatment C: abiraterone acetate

  • Experimental
    Sequence 2: abiraterone acetate

    Randomly assigned participants in Sequence 2 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule "BAC" under fasted conditions.

    Drug: Treatment A: abiraterone acetate · Drug: Treatment B: abiraterone acetate · Drug: Treatment C: abiraterone acetate

  • Experimental
    Sequence 3: abiraterone acetate

    Randomly assigned participants in Sequence 3 will receive different dose levels of abiraterone acetate (Treatment A = 250 mg; Treatment B = 500 mg; and Treatment C = 1000 mg) on Day 1 in each of the 3 treatment periods according to the randomized schedule "CBA" under fasted conditions.

    Drug: Treatment A: abiraterone acetate · Drug: Treatment B: abiraterone acetate · Drug: Treatment C: abiraterone acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration of abiraterone

    Time frame: Pre-dose and up to 96 hours post-dose each treatment period

  2. Time to reach the maximum observed plasma concentration of abiraterone

    Time frame: Pre-dose and up to 96 hours post-dose each treatment period

  3. Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration of abiraterone

    Time frame: Pre-dose and up to 96 hours post-dose each treatment period

  4. Area under the plasma concentration-time curve extrapolated to infinite time of abiraterone

    Time frame: Pre-dose and up to 96 hours post-dose each treatment period

  5. Apparent terminal elimination rate constant of abiraterone

    Time frame: Pre-dose and up to 96 hours post-dose each treatment period

  6. Apparent terminal elimination half-life of abiraterone

    Time frame: Pre-dose and up to 96 hours post-dose each treatment period

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: Up to 42 days

07

Study locations

1 site
  • Beijing, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2012, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2012
First posted
Sep 5, 2012
Start
Jul 2012
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
Sep 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01678573
Responsible party
Sponsor
First posted
Sep 5, 2012
Start date
Jul 2012
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Sep 6, 2013

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abiraterone Acetate

Start the discussion